The new partnership will support migrant children and children at risk of poverty and exclusion by strengthening resilience systems in the Western Balkans through community-based services working alongside well-established local NGO partners.

PANAMA CITY, June 30, 2026 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3-AI company, has partnered with Save the Children Hong Kong to enable Save the Children’s “Safety Nets and Resilient Families” thematic work in the Western Balkans, supporting children in underprivileged settings in Serbia and Bosnia and Herzegovina affected by migration, poverty and social exclusion.

This partnership marks Save the Children Hong Kong’s first collaboration with a cryptocurrency company and reflects a shared commitment to leveraging innovation to create meaningful social impact for children and families affected by poverty, displacement and social exclusion.

Implemented in collaboration with Save the Children, the initiative will provide humanitarian assistance to refugee and migrant children through cash vouchers and essential non-food items. As children and families seek refuge in Europe, many transit through a key country on the so-called Balkans route, Bosnia and Herzegovina, where they often face significant hardships at every stage of their journey. Save the Children is the only organization providing cash voucher assistance as a core component of its child protection response, helping families meet their essential daily needs while preserving dignity and choice.

Through the partnership, BingX will also support comprehensive protection and education services for children at risk of poverty and exclusion through community-based drop-in centres run by local NGO partners with proven expertise in the communities they serve. With one in five children living at risk of poverty and exclusion in Serbia, and one in three children living in consumption-based poverty in Bosnia and Herzegovina*, these community centres are of critical importance. They support children facing a range of challenges, including those living in substandard conditions in informal settlements, children engaged in street work, and those at risk of violence and child marriage—all of whom are disproportionately affected by extreme poverty, discrimination, and social exclusion.

At these centres, children have access to safe and supportive environments managed by experienced child protection professionals. Services include nutritious food, hygiene assistance, psychosocial support, educational guidance, legal aid, counselling, and family-strengthening programs.

Nevena Milutinovic, Save the Children Northwest Balkans Country Director, said: “Every child deserves to be protected and have a chance at a better future—and together with our partners, we work to make sure they grow up supported and included. Through our partnership with BingX, we can continue reaching children and families who need support and strengthen community drop-in centres—places that make a real difference for children facing some of the greatest barriers in the region. Children tell us that support like cash vouchers and community centres means much more than basic services. These are interventions that ensure they feel seen and supported by caring adults, make friends, feel secure, gain access to education and new opportunities, and reclaim their childhood.”

“Innovation creates its greatest value when it helps address real-world challenges. At BingX, we are committed to fostering a safe and secure future—not only within the digital asset ecosystem, but also within the communities around us. Children are the foundation of tomorrow, and every child deserves the opportunity to learn, grow, and thrive. Through our partnership with Save the Children, we are proud to help protect the future by supporting children facing poverty, displacement, and social exclusion,” said Pablo Monti, BingX Spokesperson. “This partnership also forms part of BingX’s broader commitment to supporting education, inclusion, and community resilience initiatives globally, reflecting the company’s belief that technological innovation should create positive impact beyond the digital economy.”

*Source: Child Poverty: The Cost Europe Cannot Afford Save the Children, 2025; https://resourcecentre.savethechildren.net/document/child-poverty-the-cost-europe-cannot-afford-2025

Notes to editors

The “Safety Nets and Resilient Families” thematic programme supports populations at risk in the Balkans through integrated protection, education and resilience-building interventions designed to support and strengthen locally led and community-based solutions.

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3-AI company, serving over 40 million users worldwide. Ranked among the top five global crypto derivatives exchanges and a pioneer of crypto copy trading, BingX addresses the evolving needs of users across all experience levels.

Powered by a comprehensive suite of AI-driven products and services, including futures, spot, copy trading, and TradFi offerings, BingX empowers users with innovative tools designed to enhance performance, confidence, and efficiency.

BingX has been the principal partner of Chelsea FC since 2024, and became the first official crypto exchange partner of Scuderia Ferrari HP in 2026.

For more information, please visit: https://bingx.com/

About Save the Children North West Balkans Country Office

Save the Children in North West Balkans (SCiNWB) operates for more than a decade in Bosnia and Herzegovina (Bih), Serbia and Montenegro, and oversees migration trends across the Balkans and Eastern Mediterranean. The office is deeply rooted in local communities, which is reflected in staff structure and office presence in three locations: Sarajevo (BiH) as the headquarters, Belgrade (Serbia), and Bihać (BiH), while in Montenegro, we are implementing partner-led programming. Our presence in Serbia includes the Balkans Migration and Displacement Hub providing evidence and knowledge about children affected by migration and displacement and delivers robust advocacy with and for children. 

We work in development and humanitarian contexts, working closely with communities to generate evidence to inform our learning, programming and advocacy work, support national child protection systems but also build regional/cross-border initiatives. This approach enables us to reach vulnerable populations – children affected by migration, displacement, poverty or discrimination – across multiple countries, promoting social & integrity values, safe access to services and equitable participation in policy making.

About Save the Children Hong Kong

Save the Children believes every child deserves a future. In Hong Kong and around the world, we do whatever it takes – every day and in times of crisis – so children can fulfil their rights to a healthy start in life, the opportunity to learn and protection from harm. With over 100 years of expertise, we are the world’s first and leading independent children’s organisation – transforming lives and the future.

Established in 2009, Save the Children Hong Kong is part of the global movement which operates in around 100 countries. We work with children, schools, families, communities and our supporters to deliver lasting change for children in Hong Kong and around the world.

SAN DIEGO, June 30, 2026 /PRNewswire/ — At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market opportunities through business matchmaking and global partnership discussions. While antibody-drug conjugates, other oncology and immunology biologics, and biosimilars continue to drive growth, CDMOs are gaining strategic importance amid ongoing global supply chain restructuring.

In an industry shifting from single-product competition toward platform-based and combination-therapy strategies amid geopolitical uncertainty, EirGenix addresses the challenge of finding new growth engines in mature markets through its dual-track approach. By combining targeted biosimilar development with a flexible CDMO model, the company captures high-potential oncology opportunities while helping partners accelerate global commercialization.

Breast Cancer Remains a Core Battlefield in Oncology Innovation

According to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer in 2022, making it the second most commonly diagnosed cancer worldwide. The large patient population and steadily rising treatment demand continue to drive sustained pharmaceutical investment in the field.

Market research from Grand View Research projects that the global breast cancer drug market will expand from USD 36.6 billion in 2024 to USD 69.7 billion by 2033, representing a compound annual growth rate (CAGR) of 7.1%.

HER2-positive breast cancer accounts for approximately 15% to 20% of all breast cancer cases. Historically, this subtype was associated with aggressive tumor biology and poor prognosis. However, the introduction of trastuzumab validated HER2 as a therapeutic target and reshaped the treatment paradigm.

Since then, innovation in HER2-positive therapy has accelerated. Dual-target regimens, subcutaneous formulations, and antibody-drug conjugate (ADC)-based approaches have reshaped the competitive landscape. Today, differentiation extends beyond efficacy, increasingly focusing on treatment convenience and patient experience.

Biosimilars for HER2-Positive Breast Cancer Drive EirGenix’s Next Growth Phase

The global biopharmaceutical industry is entering a major patent cliff, as approximately $300 billion of biologics are expected to lose patent protection over the next decade. This transition is creating significant opportunities for biosimilar developers across major therapeutic areas, especially in oncology and immunology. This is unlocking a vast market potential for biosimilars. While 118 biologics are set to lose exclusivity by 2034, a striking 106 of them currently have no biosimilars in development.

At the same time, global regulatory frameworks are becoming increasingly harmonized. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are aligning expectations for biosimilar approval pathways. Development requirements are increasingly focused on in vitro comparability and on pharmacokinetic bioequivalence data, reflecting a more streamlined regulatory approach. This shift is reducing reliance on large-scale Phase III clinical trials, ultimately shortening development timelines while lowering costs and clinical risk.

Against this backdrop, EirGenix has strategically prioritized HER2-positive breast cancer within its biosimilar portfolio. The company’s pipeline spans multiple modalities, including trastuzumab and pertuzumab, as well as subcutaneous combination formulations designed to improve treatment convenience and administration efficiency. In parallel, EirGenix is advancing development efforts in next-generation ADC biosimilars.

Beyond single-agent development, EirGenix is also exploring combination therapy strategies to address mechanisms of resistance in oncology treatment. These include potential co-development approaches involving ADC biosimilars alongside immune checkpoint inhibitors such as atezolizumab, as well as other targeted therapies including daratumumab.

As additional oncology biologics approach patent expiration, the company continues to evaluate and prioritize future targets across its development pipeline. This proactive portfolio strategy is designed to strengthen its positioning in the rapidly evolving immuno-oncology biosimilar landscape.

Supply Chain Restructuring Elevates the Strategic Role of CDMO Partners

Beyond biosimilars, CDMO services represent a second core pillar of EirGenix’s business strategy.

Global supply chain restructuring, the rapid rise of biotech startups, and increasing demand for biologics are reshaping outsourcing models across the pharmaceutical industry. In the United States, companies of all sizes are increasingly relying on external partners to support both development and manufacturing activities. This shift is driven by the need to reduce capital expenditure while improving R&D efficiency and operational flexibility.

With demonstrated leadership in commercial-scale GMP biologics manufacturing, EirGenix provides integrated CDMO services across the full product lifecycle. Unlike development-focused CDMOs with limited scale and late-stage capabilities, EirGenix operates a fully integrated, commercially scaled platform spanning cell line engineering, process and analytical development, technology transfer, and GMP manufacturing. This delivers strong performance across the entire value chain from early-stage development through commercialization.

Its service scope covers monoclonal antibodies, bispecific antibodies (BsAbs), and other complex biologics. By integrating these capabilities, EirGenix expands cross-border collaboration opportunities and reinforces its positioning in the global biologics outsourcing market.

EirGenix Advances Dual-Track Growth in Biosimilars and CDMO Services at BIO Convention

The United States remains the largest pharmaceutical market globally. At BIO 2026, EirGenix strengthened its international visibility by showcasing its R&D capabilities and engaging in active partnering discussions and industry networking.

The company reiterated its commitment to expanding its global footprint, with a strategic focus on capturing opportunities from biosimilar patent expirations and increasing global demand for CDMO partnerships.

EirGenix highlighted its long-term dual-track growth strategy: advancing high-value biosimilar assets while leveraging its commercial-scale development and manufacturing platform to support global clients across the entire product lifecycle.

This integrated approach is designed to accelerate development timelines for partners while improving commercialization efficiency. Ultimately, it positions EirGenix as an integrated enabler within the rapidly growing global biologics ecosystem.

Contact:

Press GeneOnline
press@geneonline.com
+886-225140360